fda compounding glp-1 enforcement news november 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA issued 25 warning letters

Pro-inflammatory adipokines (IL-6, TNF- and monocyte chemoattractant protein-1) and leptin, associated with the preservation of obesity, are raised during obesity (Reference Eskandari, Hooshmand Moghadam and Bagheri9)

[3] [4] If severe gastrointestinal symptoms occur, the bioavailability of bupropion might be temporarily reduced

The approval could unlock a big new market opportunity for Wegovy, as MASH is a form of non-alcoholic fatty liver disease (NAFLD) that affects millions of people worldwide and has been billed as pharma's next big growth area, with some analysts predicting a market potentially worth tens of billions of dollars a year

4 HEALTH BENEFITS, 1 DAILY FIBER

Stopping GLP-1 is not physically dangerous, but weight regain typically occurs without ongoing lifestyle support